# Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma

> **NCT00429559** · PHASE1,PHASE2 · COMPLETED · sponsor: **Hellenic Oncology Research Group** · enrollment: 31 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Hycamptin
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT00429559
- **Lead sponsor:** Hellenic Oncology Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2011-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00429559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00429559, "Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00429559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*